206 related articles for article (PubMed ID: 24013411)
1. Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor.
Galal SA; Abdelsamie AS; Soliman SM; Mortier J; Wolber G; Ali MM; Tokuda H; Suzuki N; Lida A; Ramadan RA; El Diwani HI
Eur J Med Chem; 2013 Nov; 69():115-24. PubMed ID: 24013411
[TBL] [Abstract][Full Text] [Related]
2. Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
Galal SA; Abdelsamie AS; Tokuda H; Suzuki N; Lida A; Elhefnawi MM; Ramadan RA; Atta MH; El Diwani HI
Eur J Med Chem; 2011 Jan; 46(1):327-40. PubMed ID: 21145626
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity.
Galal SA; Khairat SH; Ragab FA; Abdelsamie AS; Ali MM; Soliman SM; Mortier J; Wolber G; El Diwani HI
Eur J Med Chem; 2014 Oct; 86():122-32. PubMed ID: 25147154
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.
Shahin MI; Abou El Ella DA; Ismail NS; Abouzid KA
Bioorg Chem; 2014 Oct; 56():16-26. PubMed ID: 24922538
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
7. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and docking studies of novel antitumor benzimidazoles.
Omar MA; Shaker YM; Galal SA; Ali MM; Kerwin SM; Li J; Tokuda H; Ramadan RA; El Diwani HI
Bioorg Med Chem; 2012 Dec; 20(24):6989-7001. PubMed ID: 23123017
[TBL] [Abstract][Full Text] [Related]
9. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
Elsayed MS; El-Araby ME; Serya RA; El-Khatib AH; Linscheid MW; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():122-31. PubMed ID: 23063746
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
12. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
13. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
14. Sulphonamido-quinoxalines: search for anticancer agent.
Ingle R; Marathe R; Magar D; Patel HM; Surana SJ
Eur J Med Chem; 2013 Jul; 65():168-86. PubMed ID: 23708011
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.
Rodrigues FA; Bomfim Ida S; Cavalcanti BC; Pessoa Cdo Ó; Wardell JL; Wardell SM; Pinheiro AC; Kaiser CR; Nogueira TC; Low JN; Gomes LR; de Souza MV
Bioorg Med Chem Lett; 2014 Feb; 24(3):934-9. PubMed ID: 24398294
[TBL] [Abstract][Full Text] [Related]
17. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
18. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro antitumor activity of new quinoxaline derivatives.
Corona P; Carta A; Loriga M; Vitale G; Paglietti G
Eur J Med Chem; 2009 Apr; 44(4):1579-91. PubMed ID: 18774202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
